Most patient information about ovarian cancer surgery focuses on the operation itself, what’s done, how long it takes, what the cancer outcomes look like. Far less is written about what the year after surgery actually looks like. The recovery, the chemotherapy, the surveillance, the returning to work, the moments that feel like setbacks, the moments that feel like progress.
This article is for patients who have undergone cytoreductive surgery for advanced ovarian cancer, and for their families. It maps the realistic 12-month trajectory: what’s normal, what isn’t, what helps, and when to call your doctor.
Month 1: The hospital and immediate recovery
The first hospital stay after complete cytoreductive surgery, sometimes with HIPEC, is typically 7–14 days. Patients in well-run programmes with enhanced recovery (ERAS) protocols are often discharged at the shorter end of that range.
What’s normal in week 1: – Pain controlled with a combination of paracetamol, opioids (initially), and patient-controlled analgesia – Drains in place initially, removed as output decreases – Walking starts on day 1 or 2 with assistance – Diet progresses from sips to soft food to normal food over 4–6 days – Catheter usually removed by day 3–5
What’s normal in weeks 2–4: – Energy levels noticeably low; afternoon fatigue is universal – Appetite gradually returns but is smaller than pre-surgery for several weeks – Walking distance increases incrementally, from room-to-bathroom to short walks outside – Sleep is often disrupted; positional comfort takes time to find – Emotional fluctuations, relief, anxiety, occasional low mood, are common
What’s not normal and warrants a call to your team: – Fever above 38°C (100.4°F) – New severe abdominal pain, particularly with vomiting – Wound redness, increasing swelling, or discharge – Sudden shortness of breath or chest pain (rule out pulmonary embolism) – Calf pain or swelling (rule out deep vein thrombosis) – Persistent vomiting or inability to keep food down
Most post-surgical complications, if they occur, occur in the first 30 days. Vigilance is highest during this window.
Month 2: Beginning adjuvant chemotherapy
If your pathology confirms Stage III ovarian cancer, you will start adjuvant chemotherapy approximately 4–6 weeks after surgery, earlier if you’ve had neoadjuvant chemotherapy already and surgery was the interval procedure.
The standard regimen for first-line ovarian cancer is carboplatin + paclitaxel, given every 3 weeks for 6 cycles. Some patients add bevacizumab. PARP inhibitor maintenance (olaparib, niraparib, or rucaparib) follows for selected patients with BRCA mutations or HRD-positive disease.
What chemotherapy feels like in practice:
- Days 1–3 after each cycle: relatively normal, sometimes a “steroid bounce” with extra energy
- Days 4–10 after each cycle: fatigue peaks, appetite drops, sometimes nausea or mild gastrointestinal upset
- Days 11–14: low blood counts, highest infection risk, fatigue still present
- Days 15–21: gradual recovery, feeling more like yourself by the time the next cycle starts
Hair loss begins around week 2–3 of treatment, peaks around cycle 2, and is universal with paclitaxel. Scalp cooling can reduce the severity but rarely prevents it entirely. Most patients find that planning ahead, short haircut, wig or scarves arranged, helps psychologically.
The end of chemotherapy is a significant emotional milestone. Many patients report that the first weeks after the last cycle are paradoxically harder than the treatment itself: the active “doing something about the cancer” phase ends, surveillance begins, and the uncertainty becomes louder.
Months 4–6: Recovering from chemotherapy
By month 4, most patients have completed chemotherapy and entered the recovery phase. Three patterns to expect:
Physical recovery: energy returns gradually. Most patients describe feeling “70% normal” by 8 weeks after chemo ends, “85% normal” by 4 months, and “near baseline” by 6 months, though some people don’t quite return to their pre-cancer baseline.
Hair regrowth: visible new growth at 4–6 weeks after the last cycle, full coverage by 4 months. Texture and colour are sometimes different for the first 6–12 months (“chemo curls” are real). Eyebrows and eyelashes come back over months 2–4.
Neuropathy in fingers and toes, caused by paclitaxel, typically improves over 6–12 months but doesn’t always resolve completely. Mild residual neuropathy in 20–30% of patients is common.
This is also the phase where return to work, normal social activity, and exercise rebuilding becomes possible. Most patients return to part-time work around weeks 4–8 after chemotherapy ends, with full-time return by 3–4 months for those whose jobs allow it.
Surveillance from month 4 onwards
Surveillance follow-up for ovarian cancer has a clear pattern:
- Every 3 months for the first 2 years: clinical examination, CA-125 blood test
- Every 4–6 months in years 3–5: clinical examination, CA-125
- Annually after year 5: clinical examination
- Imaging (CT or MRI) based on symptoms and CA-125 trends, not routinely
The CA-125 trajectory matters more than any single value. A rising CA-125, even within the “normal” range, over three consecutive readings is a more meaningful signal than a single elevated value.
This is also the phase where the psychological work of life after cancer takes its real shape. The fear of recurrence (“scanxiety”) around each appointment is well-described and well-recognised. Cancer support groups, individual counselling, and structured mindfulness practices all have evidence for reducing this distress.
Months 6–12: Returning to a new normal
The second half of the first year is when “recovery” gives way to “living with what happened.” A few patterns most patients experience:
Physical: exercise capacity rebuilds, abdominal scars mature and become less prominent, intimate life gradually re-engages (vaginal dryness from chemotherapy and surgical menopause needs specific management, don’t suffer through it silently).
Emotional: the diagnosis stops being the centre of every day. Most patients describe a shift around 9–12 months from “I am a cancer patient” to “I had cancer.” That shift is uneven and non-linear.
Family: family members who carried the load through treatment often have their own delayed reaction, anxiety, grief, exhaustion, that doesn’t surface until the patient is visibly better. Family conversations about what each person needs are often more useful at month 9 than at month 1.
Work: full return to work is the norm for most patients by 9 months. Some patients use the experience to renegotiate roles, hours, or career paths.
What to discuss with your doctor
A few specific conversations that often get postponed but shouldn’t be:
- Bone health: surgical menopause and chemotherapy both accelerate bone loss. A baseline DEXA scan and discussion of calcium, vitamin D, and exercise should happen in the first 6 months.
- Vaginal and sexual health: vaginal dryness, dyspareunia, and reduced libido after surgical menopause are common, treatable, and substantially under-discussed. Vaginal moisturisers, local vaginal estrogen (where safe), and pelvic-floor physiotherapy all help.
- Mental health: anxiety, depression, and adjustment difficulties are common. Treatment is effective and not weakness. Specialist referral for a few sessions of cognitive-behavioural therapy or counselling is reasonable.
- Genetic testing: if not done at diagnosis, BRCA testing should be discussed during the recovery phase, especially if you have children or siblings.
- PARP inhibitor maintenance: for eligible patients, this is now a standard part of post-chemotherapy care. If it wasn’t discussed at the end of chemo, ask about eligibility.
Recurrence, the realistic conversation
Ovarian cancer can recur. The probability depends on stage at diagnosis, completeness of cytoreduction, response to chemotherapy, and biological factors including BRCA/HRD status. The clinical realities most patients aren’t told:
- Recurrence is not failure of treatment. It is the natural history of ovarian cancer, which is increasingly managed as a chronic disease with multiple lines of treatment available.
- Modern treatment of recurrent ovarian cancer, including secondary cytoreductive surgery in selected patients, PARP inhibitors, and platinum re-challenge, has substantially extended survival in the recurrent setting.
- The conversation at recurrence is similar to the conversation at first diagnosis: multidisciplinary review, BRCA-informed treatment selection, surgical opinion where appropriate.
Knowing this in advance, rather than learning it under emotional pressure at the time of recurrence, helps families plan and reduces shock.
The bottom line
The year after cytoreductive surgery and chemotherapy for ovarian cancer is structured, predictable in most patients, and generally tolerable with the right support and the right surveillance. The major sources of distress, fatigue, neuropathy, surgical menopause symptoms, fear of recurrence, are all addressable when they’re named and discussed openly.
The patients who do best are those who treat the recovery phase as active care, not passive waiting. Specific conversations about bone health, vaginal health, mental health, and surveillance schedule are part of the work of recovery, not optional add-ons.
About the author
This article was reviewed by Dr. Nishtha Tripathi Patel (MBBS, DGO, DNB, Fellowship in Gynaecological Oncology, ESGO-certified), an ESGO-certified gynaecological oncosurgeon in Ahmedabad with extensive experience in cytoreductive surgery, HIPEC, and surveillance care for ovarian cancer. Reach her practice at +91 76988 00333.